CJC-1295: Research on a Long-Acting GHRH Analog

CJC-1295 is a synthetic analog of growth-hormone-releasing hormone. It is built on the GHRH(1-29) sequence, with changes meant to make it stay around longer. Its role is the same as other GHRH compounds, signaling the pituitary to release growth hormone, but over a longer period. This is an educational summary and does not describe any human use.

Designed to last longer

Duration is the main thing that defines CJC-1295 in the research. A clinical study reported that growth hormone and IGF-1 stayed elevated for a long time after administration, which fits the extended half-life design (Teichman et al., J Clin Endocrinol Metab, 2006). [1] A longer signaling window is the purpose of the modification.

Same GHRH(1-29) core

CJC-1295 keeps the GHRH(1-29) active core described in structure-activity research (Cervini et al., J Med Chem, 1998). [2] That is why it gets studied together with sermorelin and tesamorelin as one family of GHRH analogs.

Detecting it analytically

CJC-1295 has also been characterized with analytical methods, for example ways to identify it in plasma. That work gives useful background when confirming what a sample is (Henninge et al., Drug Test Anal, 2010). [3]

Note: The findings come from preclinical and early clinical research. Research-grade material is for laboratory Research Use Only and is not for human or veterinary use.

FAQ

Why is CJC-1295 called long-acting?

Changes to the GHRH scaffold are meant to slow how fast it breaks down, so it can stimulate growth-hormone release over a longer window in research models.

References

1. Teichman et al. — prolonged GH/IGF-1 stimulation by CJC-1295 (JCEM, 2006)
2. Cervini et al. — hGHRH(1-29)NH2 structure-activity (J Med Chem, 1998)
3. Henninge et al. — identification of CJC-1295 in plasma (Drug Test Anal, 2010)
4. Sermorelin guide (related GHRH compound)